Figure 4.
(a) Proportion of the amount of TGF-β inhibitor used for the entire treatment duration, (b) dynamics of the N1-N2 system and (c) tumour dynamics under TGF-β inhibitor control starting at different initial conditions Q1, Q2, Q3, Q4.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.